Farrar Gill, Weber Christopher J, Rabinovici Gil D
GE HealthCare, Little Chalfont, Buckinghamshire, UK.
Alzheimers Association, Chicago, IL, USA.
J Prev Alzheimers Dis. 2025 Jan;12(1):100008. doi: 10.1016/j.tjpad.2024.100008. Epub 2025 Jan 1.
A 24-30 Centiloid (CL) threshold was collectively considered by a group of global dementia experts as a practical and implementable cut-off for anti-amyloid therapy intervention, in Alzheimer's disease patients who have been diagnosed at the mild cognitive impairment or mild dementia stage of their disease. Though additional validation is needed, knowledge of this threshold would be valuable to those involved in diagnosing and treating patients in the new AD care pathways, as well as entry into clinical trials. Therapy monitoring to determine future treatment response and assess amyloid clearance can be accomplished with amyloid PET with some technical details still to be elucidated.
一组全球痴呆症专家共同认为，对于已被诊断处于疾病轻度认知障碍或轻度痴呆阶段的阿尔茨海默病患者，24 - 30 分位值（CL）的阈值可作为抗淀粉样蛋白治疗干预的实用且可实施的临界值。尽管还需要进一步验证，但了解这一阈值对于参与新的阿尔茨海默病护理途径中患者诊断和治疗的人员以及进入临床试验的人员来说将是有价值的。通过淀粉样蛋白正电子发射断层扫描（PET）可以实现治疗监测，以确定未来的治疗反应并评估淀粉样蛋白清除情况，不过仍有一些技术细节有待阐明。
